| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| Xcyte Therapies, Inc. |
| 1124 Columbia Street, Suite 130, Seattle, WA 98104 * (206) 262-6200 |
| Business Description | The company is utilizing novel technologies to develop therapeutic products that generate effective immune responses to treat cancer and infectious diseases. |
|
Filing Information Not yet | |||
| To Trade As | XCYT (NASNTL) | Industry | Pharmaceutical (SIC 2834) |
| Type of Stock Offered | Common Shares | Filing Date | 12/22/2000 |
| Domestic Shares Filed | 0 | Filing Price | - - |
| Foreign Shares Filed | 0 | Offering Amount | $75,000,000 |
| Company Shares | 0 | Est. Expenses | - - |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| SG Cowen | Lead Manager | (212) 495-6000 |
| Dain Rauscher Wessels | Co-manager | (612) 371-2818 |
| First Security Van Kasper | Co-manager | (415) 954-0650 |
| U.S. Bancorp Piper Jaffray | Co-manager | (612) 342-6220 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 9 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/1997 | 12/31/1998 | 12/31/1999 | 9/30/1999 | 9/30/2000 | ||
| Revenues | - | - | 0.100 | - | 0.016 | 0.000 | 0.044 |
| Income from Oper. | - | - | -3.449 | -5.744 | 7.125 | -4.734 | -8.750 |
| Net Income | - | - | -3.288 | -5.446 | -6.947 | -4.502 | -8.472 |
| E.P.S | - | - | -0.690 | -0.860 | -1.150 | -0.740 | -1.420 |
| Revenue Growth (%) | - | - | - | - | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | 44,531.25 | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -5.57 | -4.09 | -8.06 | ||||
| Cash Flow - Inv. | 4.39 | 6.78 | 5.31 | ||||
| Cash Flow - Fin. | 0.04 | 0.12 | 28.38 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 9/30/2000 | Financial Ratios | ||||
| Total Assets | 30.34 | Current Assets | 28.05 | Current Ratio | 16.90 |
| Total Liab. | 51.56 | Current Liab. | 1.66 | Debt Ratio | 169.98% |
| Total Equity | -21.23 | Working Cap. | 26.39 | Debt to Equity Ratio | - |
| Cash | 25.76 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for clinical trials, research and development activities, expansion of manufacturing capacity and general corporate purposes and working capital. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Venture Law Group |
| Bank's Law Firm | Shearman & Sterling |
| Registrar/Transfer Agent | Computershare Invstor Services LLC |
| Auditor | Pricewaterhouse Coopers LLC |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| ARCH Venture Corporation | 16.20 | |
| MPM Asset Management LLC | 13.70 | |
| Spout Group | 13.50 | |
| Alta Partners | 12.40 | |
| Tredegar Investments | 6.60 | |
| Note: represents ownership of 5% or more prior to the offering. | ||